insights_auto
Why is ONCY down 15,03%?
Dive Deeperchevron_right
ONCY:NASDAQ
Oncolytics Biotech Inc
0,47 $
arrow_downward
-15,03%(-0,084) 1D
0,47 $
arrow_upward
+0,08% (+0,00040)bedtimeAfter hours
Closed: 12 հոկ, 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ONCY...
Open
0,57 $
High
0,59 $
Low
0,44 $
Mkt. cap
61,73 մլն
Avg. vol.
1,08 մլն
Volume
3,29 մլն
52-wk high
1,32 $
52-wk low
0,44 $
Beta
1,15
Shares outstanding
127,51 մլն
No. of employees
29
Open
0,57 $
High
0,59 $
Low
0,44 $
Mkt. cap
61,73 մլն
Avg. vol.
1,08 մլն
Volume
3,29 մլն
52-wk high
1,32 $
52-wk low
0,44 $
Beta
1,15
Shares outstanding
127,51 մլն
No. of employees
29
News stories
From web sources and news partners
TipRanks
·
2 ժամ առաջ
Oncolytics Biotech Extends Pelareorep Patent Protection Into Late 2040s
Investing.com Canada
·
3 ժամ առաջ
Oncolytics receives cancer immunotherapy patent in multiple countries By Investing.com
Stock Titan
·
3 ժամ առաջ
Patent protection for Oncolytics’ cancer therapy could extend into the late 2040s.
Investing.com Nigeria
·
1 օր առաջ
Form DEF 14A CG Oncology Inc For: 11 October By Investing.com
Profile
Oncolytics Biotech Inc. is a biotech company headquartered in San Diego, California, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
About Oncolytics Biotech Inc